Mihaela Necula

TL;DR: Since the fibril specific antibodies are conformation dependent, sequence-independent, and recognize epitopes that are distinct from those present in prefibrillar oligomers, they may have broad utility for detecting and characterizing the accumulation of amyloid fibrils and fibrillare type oligomers in degenerative diseases.

TL;DR: The results indicate that oligomers are not an obligate intermediate in the fibril formation pathway and suggest that small molecule inhibitors are useful for clarifying the mechanisms underlying protein aggregation and may represent potential therapeutic agents that target fundamental disease mechanisms.

TL;DR: The data show that Abeta oligomer formation is inhibited by promoting fibril formation, which suggests that the relative pathological significance of oligomers and fibrils may be tested in vivo using methylene blue.

TL;DR: In vitro observations suggest that preventive vaccination may protect from AD or may delay the onset of the disease, whereas therapeutic vaccination cannot disrupt the toxic oligomers and may only minimally alleviate preexisting AD pathology.

TL;DR: Methylene blue, which is well tolerated and used in humans, has therapeutic potential for Huntington's disease and inhibited recombinant protein aggregation in vitro, even when added to preformed oligomers and fibrils.